On Jan. 3, 2021, Humanigen announced that a manuscript detailing the results of an analysis of CRP levels from the LIVE-AIR Phase 3 study was available on medRxiv .

The results indicate the greatest clinical benefit of lenzilumab treatment may be achieved in hospitalized COVID-19 patients with lower baseline CRP levels, which typically occur earlier in the progression of the disease.